Introduction
============

Keratoconus (KTCN) is an eye disease characterized by progressive thinning and conical protrusion of the cornea ([@ref-18]). The structural abnormalities in different layers of corneal tissue result in altered refractive powers and a loss of visual function ([@ref-42]). The first symptoms of KTCN usually appear during puberty or early in the third decade of life ([@ref-42]). The management of this condition depends on the disease stage and includes visual correction by contact lenses, corneal collagen cross-linking, or corneal transplant surgery ([@ref-45]; [@ref-54]). The incidence of KTCN is one in 2,000 individuals in the general population ([@ref-42]). However, the incidence may vary depending on the geographic location and ethnicity of the studied population. The estimated incidence of KTCN is higher in Indians, Chinese, Pacific, and Maori ethnicities compared with Caucasians ([@ref-40]; [@ref-10]; [@ref-25]; [@ref-39]; [@ref-12]; [@ref-11]). The environmental factors, such as eye rubbing or contact lens wear, influence disease development ([@ref-13]). However, genetic triggers also play an important role in KTCN ([@ref-18]; [@ref-1]). Several genomic strategies have been implemented for finding candidate genes, including both simple molecular techniques and high-throughput technologies ([@ref-18]; [@ref-1]; [@ref-7]; [@ref-34]; [@ref-53]; [@ref-30]).

Linkage studies, performed in KTCN families, have led to the identification of multiple chromosomal regions linked to KTCN, including two replicated loci at 5q ([@ref-51]; [@ref-29]; [@ref-3]; [@ref-43]; [@ref-6]). The genome-wide association studies have detected variants mapped near *HGF*, *COL5A1*, *FOXO1*, *RAB3GAP1*, or *ZNF469*, associated with KTCN risk ([@ref-28]; [@ref-5]; [@ref-14]; [@ref-31]). However, their contribution to KTCN needs to be clarified. Several candidate genes for KTCN have also been identified using Sanger sequencing or next-generation sequencing including *VSX1*, *SOD1* and *DOCK9* or *SKP1*, *MPDZ, FLG, PPIP5K2*, and *PCSK1*, respectively ([@ref-15]; [@ref-21], [@ref-19]; [@ref-52]; [@ref-32]; [@ref-22]; [@ref-33]). However, variants detected in those genes were present in a small fraction of KTCN patients or particular populations only.

Analysis of transcriptome profiles of human KTCN and non-KTCN corneas by a high-throughput RNA sequencing (RNA-Seq) showed the deregulation of numerous genes in KTCN corneas ([@ref-16]). The significant downregulation was observed among genes in collagen synthesis and maturation pathways, as well as in the TGF-β, Hippo and Wnt signaling pathways ([@ref-16]). The results of subsequent RNA studies further support the potential role of genes involved in the extracellular matrix, TGF-β and Wnt molecular cascades in KTCN pathogenesis ([@ref-23]; [@ref-57]; [@ref-47]). Since these signaling pathways influence the corneal organization and play a role in the regulation of extracellular matrix components, the genes encoding the core elements of the mentioned pathways were proposed as novel candidate genes for KTCN.

To assess the involvement of new genetic variants in KTCN etiology, we performed a further molecular investigation of corneas of Polish patients with KTCN, previously tested by RNA-Seq, using exome sequencing (ES) approach.

Materials and Methods
=====================

Patients
--------

All patients with KTCN underwent a complete ophthalmic evaluation in the Department of Ophthalmology, Medical University of Warsaw, Poland. The KTCN diagnosis was made based on the criteria previously described ([@ref-16]; [@ref-20]). The study protocol was approved by the Institutional Review Board at Poznan University of Medical Sciences (453/14; 755/19). All individuals provided informed consent after the possible consequences of the study were explained, in accordance with the Declaration of Helsinki.

### Material collection and DNA extraction

The pairs of whole corneal tissues and blood samples were obtained from previously evaluated five KTCN patients (KC15, KC16, KC17, KC18, and KC19) ([@ref-16]) undergoing a penetrating keratoplasty procedure. The clinical characteristics of these patients are presented in [Table S1](#supp-1){ref-type="supplementary-material"}. Genomic DNA samples from the corneas were extracted using the Cells and Tissue DNA Isolation Kit (Norgen Biotek, Thorold, ON, Canada) according to the manufacturer's protocol. Genomic DNA samples were isolated from the blood lymphocytes using the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany), as previously described ([@ref-20]).

### Exome sequencing

This pilot ES study was conducted with 50 ng of genomic DNA of whole corneal tissues (KC15, KC16, KC17, KC18, and KC19) using the SureSelectQXT Reagent Kit combined with the SureSelectXT Human All Exon V5 (Agilent Technologies, Cedar Creek, TX, USA) according to manufacturer's instruction. Prepared libraries were paired-end sequenced (2 × 100 bp) on an Illumina HiSeq1500 (Illumina, San Diego, CA, USA). For each cornea sample \> 80 million read pairs were generated resulted in \>100× of mean coverage. Sequence readouts were initially analyzed with bcl2fastq software to generate reads in fastq format. These reads were mapped against a human genome reference sequence (GRCh37) using the Burrows--Wheeler Alignment (BWA), which was followed by BAM post-processing and variant calling using HaplotypeCaller and the GATK suite ([@ref-36]). Finally, ANNOVAR ([@ref-56]) was used to annotate relevant information about gene names, predicted variant pathogenicity, reference allele frequencies and metadata from external resources and then to add these to the variant call format (VCF) file.

### Variants selection

Sequence variants identified in KTCN corneas were filtered in a step-wise manner to exclude synonymous variants and variants with minor allele frequency (MAF) greater than 0.01 in our internal exome database (DMG) consisting of 3,000 Polish individuals, ExAC Browser (<http://exac.broadinstitute.org/>), GnomAD database (<https://gnomad.broadinstitute.org/>), and the 1,000 Genomes Project (<http://www.1000genomes.org>). Moreover, variants predicted as neutral by MutationTaster ([@ref-46]), PolyPhen-2 ([@ref-2]), LRT ([@ref-8]) and SIFT ([@ref-27]) tools were filtered out. The additional exclusion criterion was negative conservation scores in PhyloP ([@ref-41]) analysis.

### Sanger sequencing

To confirm variants detected by ES in five KTCN corneas, Sanger sequencing of DNA in matching blood samples was performed. Briefly, fragments of genes containing particular variants were amplified using *Taq* DNA Polymerase (Thermo Scientific, San Jose, CA, USA). Following purifications with the use of FastAP Thermosensitive Alkaline Phosphatase and Exonuclease I (Thermo Scientific, San Jose, CA, USA), the amplicons were sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Inc., Foster City, CA, USA). Samples were analyzed on the ABI Prism 3730xl genetic analyzer (Applied Biosystems Inc., Foster City, CA, USA). Sequences were assembled using Sequencher 5.0. Software (GeneCodes Corporation, Ann Arbor, MI, USA).

### Pathway overrepresentation analysis

The overrepresentation analysis of molecular pathways among genes with identified sequence variants, which met the filtering criteria, was performed using the ConsensusPathDB tool ([@ref-17]). Only pathways with *p*-value ≤ 0.01 and sharing at least two genes with our gene set were analyzed.

### Ethnically-matched control datasets

For comparison purposes, the datasets comprising ES data of five randomly selected Polish individuals without ocular abnormalities and five Polish patients with high myopia (HM) were used. Variants from control ES data were selected using the same filtering criteria as we used for the KTCN study, followed by enrichment analyses.

### Expression analysis

Expression levels of selected genes from overrepresented pathways, given in the gene-level transcripts per million (TPM), were obtained from the RNA-Seq study, which has been previously performed in the same corneal material ([@ref-16]). The expression values of the particular genes were compared between corneal samples in which variant(s) was identified and in samples without the analyzed variant.

Results
=======

This pilot ES screening of KTCN corneas revealed 117 potentially relevant variants with MAF ≤ 0.01 in our internal DMG cohort and public databases and fulfilling all of the remaining filtering criteria ([Table S2](#supp-2){ref-type="supplementary-material"}). Genes with identified rare nucleotide variants were enriched in 14 molecular pathways, including Wnt signaling (*VANGL1*, *WNT1*, *PPP3CC*, *LRP6*, *FZD2*) and focal adhesion (*BIRC2*, *PAK6*, *COL4A4*, *PPP1R12A*, *PTK6*) pathways ([Table 1](#table-1){ref-type="table"}). The analysis of functional interactions between genes from overrepresented molecular pathways allowed for further narrowing the number of candidate KTCN variants ([Table 2](#table-2){ref-type="table"}).
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###### Top pathways overrepresented across the genes with identified sequence variants in KTCN corneas detected by ConsensusPathDB server (*p*-value cutoff 0.01).

![](peerj-08-8982-g001)

  Pathway name                                                                     Source         Genes^[a](#table-1fn1){ref-type="fn"}^              *p*-Value
  -------------------------------------------------------------------------------- -------------- --------------------------------------------------- -------------
  Disassembly of the destruction complex and recruitment of AXIN to the membrane   Reactome       *FZD2*, *LRP6*, *WNT1*                              0.000873181
  Wnt signaling                                                                    Wikipathways   *VANGL1*, *WNT1*, *PPP3CC*, *LRP6*, *FZD2*          0.000893629
  Type I hemidesmosome assembly                                                    Reactome       *PLEC*, *COL17A1*                                   0.001477943
  Wnt signaling in kidney disease                                                  Wikipathways   *WNT1*, *LRP6*, *FZD2*                              0.001788119
  Wnt signaling pathway - *Homo sapiens* (human)                                   KEGG           *VANGL1*, *WNT1*, *PPP3CC*, *LRP6*, *FZD2*          0.002830193
  RAB GEFs exchange GTP for GDP on RABs                                            Reactome       *ANKRD27*, *DENND1A*, *RABGEF1*, *DENND4C*          0.002959219
  The activation of arylsulfatases                                                 Reactome       *ARSD*, *ARSB*                                      0.003148218
  Epithelial to mesenchymal transition in colorectal cancer                        Wikipathways   *WNT1*, *COL4A4*, *LRP6*, *FZD2*, *MEF2D*           0.003952926
  cGMP-PKG signaling pathway - *Homo sapiens* (human)                              KEGG           *ATP2A1*, *PIK3CG*, *PPP1R12A*, *PPP3CC*, *MEF2D*   0.004277236
  MicroRNAs in cardiomyocyte hypertrophy                                           Wikipathways   *HDAC9*, *FZD2*, *LRP6*, *PIK3CG*                   0.004456905
  Wnt-beta-catenin signaling pathway in Leukemia                                   Wikipathways   *WNT1*, *LRP6*                                      0.008974682
  Rab regulation of trafficking                                                    Reactome       *ANKRD27*, *DENND1A*, *RABGEF1*, *DENND4C*          0.009329868
  Focal adhesion                                                                   Wikipathways   *BIRC2*, *PAK6*, *COL4A4*, *PPP1R12A*, *PTK6*       0.009582658
  Regulation of RAS by GAPs                                                        Reactome       *NF1*, *SPRED2*                                     0.009787951

**Note:**

Analyzes were performed in genes with variants fulfilling the filtering criteria: (i) MAF ≤ 0.01 in our internal database, the ExAC Browser, GnomAD database and the 1,000 Genomes Project Variants; (ii) positive conservation scores in PhyloP; (iii) pathogenic/damaging in MutationTaster, PolyPhen2, LRT and SIFT tools.
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###### The list of nonsynonymous sequence variants in genes from Wnt signaling and focal adhesion pathways, identified in KTCN corneas in ES.

![](peerj-08-8982-g002)

  Identifier   Gene                               Acession number                    Position[^a^](#table-2fn1){ref-type="fn"}   cDNA         Protein      DMG[^b^](#table-2fn2){ref-type="fn"}   GnomAD^[c](#table-2fn3){ref-type="fn"}^   Rs_id^[d](#table-2fn4){ref-type="fn"}^
  ------------ ---------------------------------- ---------------------------------- ------------------------------------------- ------------ ------------ -------------------------------------- ----------------------------------------- ----------------------------------------
  KC15         *WNT1*                             [NM_005430.3](NM_005430.3)         chr12:49375373G\>T                          c.1063G\>T   p.(V355F)    0                                      NA[^e^](#table-2fn5){ref-type="fn"}       rs387907358
  *PTK6*       [NM_005975.3](NM_005975.3)         chr20:62161533G\>T                 c.1066C\>A                                  p.(P356T)    0            NA                                     NA                                        
  KC16         *FZD2*                             [NM_001466.3](NM_001466.3)         chr17:42636294G\>A                          c.1238G\>A   p.(R413Q)    0                                      0.00002396                                rs758351214
  *VANGL1*     [NM_001172411.1](NM_001172411.1)   chr1:116194075C\>T                 c.41C\>T                                    p.(S14L)     0            NA                                     NA                                        
  *COL4A4*     [NM_000092.4](NM_000092.4)         chr2:227924157C\>T                 c.2347G\>A                                  p.(G783R)    0.000333     NA                                     rs1202230056                              
  KC17         *LRP6*                             [NM_002336.2](NM_002336.2)         chr12:12274080G\>A                          c.4822C\>T   p.(P1608S)   0                                      NA                                        NA
  *PPP3CC*     [NM_001243975.1](NM_001243975.1)   chr8:22389795T\>C                  c.1199T\>C                                  p.(M400T)    0            NA                                     NA                                        
  KC18         *BIRC2*                            [NM_001166.4](NM_001166.4)         chr11:102248388A\>G                         c.1528A\>G   p.(I510V)    0.001                                  0.00002148                                rs749829698
  KC19         *PPP1R12A*                         [NM_001244992.1](NM_001244992.1)   chr12:80266702T\>C                          c.254A\>G    p.(N85S)     0.000667                               0.00002422                                rs370959842
  *PAK6*       [NM_001276717.1](NM_001276717.1)   chr15:40566454C\>A                 c.1855C\>A                                  p.(P619T)    0            NA                                     NA                                        

**Notes:**

Human Genome Browser---hg19 assembly (GRCh37).

Minor allele frequency based on internal control exome database covering of 3,000 Polish individuals; Department of Medical Genetics (DMG), Medical University of Warsaw, Warsaw, Poland.

Minor allele frequency based on GnomAD database v2.1.2.

NCBI dbSNP Build 151.

Not available.

Sanger sequencing performed in blood samples derived from the five studied individuals confirmed all variants identified with the use of ES in matched corneas.

The overrepresentation analysis performed among genes filtered in a step-wise manner in control datasets revealed an enrichment in 16 (i.e., O-linked glycosylation, C-type lectin receptors, termination of O-glycan biosynthesis, nucleotide-binding oligomerization domain) and nine (i.e., cargo recognition for clathrin-mediated endocytosis VLDL clearance, glyoxylate and dicarboxylate metabolism, statin pathway DNA damage recognition in GG-NER) pathways in HM patients and individuals without ocular disease, respectively. No genes involved in pathways enriched in KTCN corneas were overrepresented in our control sample sets containing randomly selected Polish individuals without ocular abnormalities (*n* = 5) and Polish patients with HM (*n* = 5).

The TPM values of genes from overrepresented pathways in corneas of patients carrying particular gene variants and in KTCN individuals without the analyzed gene variation were calculated based on our previous RNA-Seq study data ([@ref-16]). The expression values of the genes varied between patients with particular variants and the mean expression values of the same genes in the KTCN individuals without these variants. The expression profile of genes from overrepresented pathways in KTCN corneas is presented in [Table 3](#table-3){ref-type="table"}.
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###### The expression of genes with rare variants identified in ES analysis.
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  ------------------------------------------------------------------------------------------
  Pathway          Gene symbol/\   KC_15    KC_16    KC_17    KC_18    KC_19    Mean\
                   variant                                                      expression
  ---------------- --------------- -------- -------- -------- -------- -------- ------------
  Wnt Signaling    *WNT1*\         0.051    0.000    0.000    0.018    0.023    0.0103
                   c.1063G\>T                                                   

  Focal Adhesion   *PTK6*\         27.705   31.413   22.991   25.809   26.031   26.5610
                   c.1066C\>A                                                   

  Wnt Signaling    *FZD2*\         1.254    0.151    2.988    0.453    0.544    1.3098
                   c.1238G\>A                                                   

  Wnt Signaling    *VANGL1*\       4.655    3.581    4.129    3.132    5.074    4.2475
                   c.41C\>T                                                     

  Focal Adhesion   *COL4A4*\       8.802    8.487    15.100   5.863    7.398    9.2908
                   c.2347G\>A                                                   

  Wnt Signaling    *LRP6*\         14.144   13.303   11.900   11.515   12.581   12.8858
                   c.4822C\>T                                                   

  Wnt Signaling    *PPP3CC*\       12.523   14.479   9.580    8.556    10.525   11.5208
                   c.1199T\>C                                                   

  Focal Adhesion   *BIRC2*\        42.675   45.517   32.853   30.261   40.725   40.4425
                   c.1528A\>G                                                   

  Focal Adhesion   *PPP1R12A*\     83.939   83.438   61.009   55.103   76.460   70.8723
                   c.254A\>G                                                    

  Focal Adhesion   *PAK6*\         8.818    7.144    5.704    4.970    6.011    6.6590
                   c.1855C\>A                                                   
  ------------------------------------------------------------------------------------------

**Note:**

Grey color indicates the expression level in samples in which variant was present, and white color indicates the expression level of genes in samples without the presence of the analyzed variant.

The data were deposited in the freely accessible ClinVar database (submission ID: [SUB3758236](SUB3758236) and [SUB4926771](SUB4926771)).

Discussion
==========

The rapid development of next-generation DNA sequencing methods has greatly improved the ability to detect genetic variations ([@ref-24]). However, KTCN, like many other ophthalmic diseases, displays genetic heterogeneity hindering the identification of a factor unambiguously influencing its development ([@ref-18]; [@ref-49]).

The results of this pilot ES study of corneas obtained from five KTCN patients undergoing penetrating keratoplasty revealed various rare possibly pathogenic variants in genes that were overrepresented in several molecular pathways, including the Wnt signaling and focal adhesion. Interestingly, these pathways have been proposed as involved in KTCN etiology based on our previous RNA-Seq study, performed in experimental material derived from the same KTCN patients, as well as other experiments ([@ref-16]; [@ref-23]; [@ref-57]; [@ref-47]). In addition, each of five patients had at least one variant in genes from these particular pathways. Among genes from overrepresentation gene sets were *LRP6, FZD2*, *COL4A4*, and *WNT1*.

Ocular cells, including corneal epithelial stem cells, express components of the Wnt/β-catenin signaling pathway during eye development ([@ref-38]). The *LRP6* gene encodes the low-density lipoprotein receptor-related protein, which is a component of a Wnt receptor complex. This complex is involved in Wnt ligands binding resulting in the nuclear translocation of β-catenin and regulation of the transcription of target genes ([@ref-60]). Knock-out of β-catenin or its both co-receptors (*Lrp5* and *Lrp6*) in mouse corneal stromal cells resulted in premature stratification of the corneal epithelium, suggesting these genes play a role in the regulation of corneal morphogenesis ([@ref-60]). In this study, the expression of *LRP6* in the cornea of the carrier of variant c.4822C\>T (KC17) was unchanged compared to the other four KTCN individuals. However, since this variant was identified in KC17 patient in combination with another variant in the gene of Wnt signaling pathway (*PPP3CC*), we suggest that this variant might be a part of the specific combination of KTCN variants and its identification is not incidental.

The *FZD2* gene encodes frizzled class receptor 2, another protein functioning as Wnt ligands receptor and regulating the eye development through Wnt/β-catenin signaling. Xenopus frizzled-2, a homolog of the human frizzled receptor, is highly expressed in the embryo, including the developing eye ([@ref-9]). Interestingly, a significant increase of mRNA and protein expression of secreted frizzled-related protein 1 (SFRP1), which is a Wnt antagonist, has been detected in KTCN corneal epithelium and corneal buttons ([@ref-50]; [@ref-58]). In contrast, tear SFRP1 level has been significantly decreased in KTCN patients compared to control individuals ([@ref-59]). The c.1238G\>A variant in *FZD2* was identified in the cornea of KC16 patient in combination with c.41C\>T variant in *VANGL1* (Wnt signaling) and c.2347G\>A variant in *COL4A4* (focal adhesion). It is known that collagens are major components of human corneas and the thinning of corneal stroma in KTCN may be the final effect of a disorganized collagen lamellae arrangement ([@ref-37]; [@ref-35]). The *COL4A4* gene is expressed in human cornea ([@ref-16]) and based on several studies it has been reported as a candidate gene for KTCN ([@ref-48]; [@ref-55]; [@ref-26]; [@ref-44]). However, genetic analyses of this gene in different populations have given ambiguous results about the role of *COL4A4* in KTCN development ([@ref-48]; [@ref-55]; [@ref-26]; [@ref-44]). While there was no difference in expression of *COL4A4* and *VANGL1* in the patient's cornea, the expression value of *FZD2* in the patient KC16 was lower compared to the expression observed in the other four KTCN individuals. However, further research should be performed to interpret the obtained data.

The combination of variants in *WNT1* and *PTK6* was revealed in the patient KC15. *PTK6* encodes tyrosine kinase 6 protein, which is involved in focal adhesion, as well as in GTPases and MAP kinases regulation. Signaling by PTK6 is implicated in controlling the differentiation of normal epithelium and tumor growth ([@ref-4]). However, there is no report about the role of *PTK6* in the maintenance of corneal epithelium.

Also, in KC18 and KC19 patients, variants in other elements (*BIRC2* and *PAK6* with *PPP1R12A*, respectively) of Wnt signaling and/or focal adhesion pathways were observed. These results further suggest that the alteration of genes regulating these signaling pathways might be an important risk factor for KTCN.

To determine the likelihood of seeing the overrepresentation of genes from Wnt signaling and focal adhesion in KTCN samples by chance, we performed analyses of exome data of five randomly selected Polish individuals without eye disease, as well as five Polish individuals with HM. Variants from control ES data were selected using the same filtering criteria as we used for the KTCN study, followed by enrichment analyses. No genes involved in Wnt signaling or focal adhesion pathways were overrepresented in our control sample sets, confirming that enrichment of variants in genes from these pathways in KTCN individuals was not incidental.

The small sample size disabled a reliable statistical analysis and due to this limitation, the general conclusions could not be made. However, the results of this pilot study gave additional insight into the role of the Wnt signaling and/or focal adhesion pathways in KTCN development and showed the possible indications for further KTCN research. The identification of rare variants in different genes further supports the heterogeneity of KTCN with multiple genes underlying its pathogenesis ([@ref-18]; [@ref-1]; [@ref-7]; [@ref-34]; [@ref-53]).

Conclusions
===========

Summarizing, this first pilot ES profiling of human KTCN corneas indicates that the accumulation of variants in several genes from Wnt signaling and/or focal adhesion pathways might cause the phenotypic effect and further explain the involvement of these pathways in KTCN. Moreover, it also supports the hypothesis about the complex basis of KTCN. Since five patients were evaluated, the role of variants in genes of these overrepresented pathways in KTCN etiology should be further elucidated in a larger group of patients using high throughput methods.
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